Search Results 181-190 of 11437 for ���������������������������:za33���24������ ������������������������ ������

  1. 13CARBON-Based Deep Labelling of Bone Marrow Cells to Map Their Utilization of Extracellular Metabolites - Mayo Clinic

    Rochester, Minnesota: 24-003478. Sponsor Protocol Number: 24-003478. About this study. The purpose of this studyis to evaluate differences in the amount of ...

  2. Ventricular tachycardia - Doctors and departments - Mayo Clinic

    Ventricular tachycardia: When a rapid heartbeat is life-threatening.

  3. Clinical trials - Oncology (Medical)

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...

  4. Publications - Razvan M. Chirila, M.D. - Mayo Clinic

    2019 Oct; 34 (10):2288-2289 Epub 2019 July 24. View PubMed; Failing JJ, Dudek OA, Marin Acevedo JA, Chirila RM, Dong H, Markovic SN, Dronca RS. Biomarkers of ...

  5. Clinical trials - Oncology (Medical)

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...

  6. https://www.mayoclinic.org/spanish_procedure_concepts.xml

  7. Tricuspid valve repair and tricuspid valve replacement - Doctors & Departments - Mayo Clinic

    These heart surgeries treat tricuspid valve regurgitation and stenosis and Ebstein anomaly, a type of congenital heart defect. Learn how they're done.

  8. Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma - Mayo Clinic

    Rochester, Minnesota: 24-011608; Scottsdale/Phoenix, Arizona: 24-011608. NCT ID: NCT06608927. Sponsor Protocol Number: PRISM-1. About this study. The purpose ...

  9. https://www.mayoclinic.org/arabic_procedure_concepts.xml

  10. Oncology (Medical) - Clinical trials - Mayo Clinic

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...